PA41-BMD: Clinical Chemistry Summary

DTTID: 108-020-006-000-7
Study Number: 108020006
Study Type: 5-Day Toxicity
Species/Strain: Rat/Harlan Sprague Dawley

Test Compound: 1,2-Dichlorobenzene
CAS Number: 95-50-1
DTXSID: DTXSID6020430

Date: 19 Jun 2025
Time: 12:38:02 PM

Female Clinical Chemistry Data and BMD Values

	Treatment Groups (ppm) & BMD Values (ppm)								
	0	1	10	30	100	250	500	BMD_{1Std}	$BMDL_{1Std}$
A/G Ratio	3.02 ± 0.11[10]**	3.12 ± 0.07[5]	2.96 ± 0.14[5]	2.78 ± 0.19[5]	3.06 ± 0.12[5]	3.39 ± 0.11[5]	3.69 ± 0.11[5]**	182.3	99.4
Bile Salts/Acids (µmol/L)	6.0 ± 1.3[10]**	4.6 ± 0.8[5]	9.3 ± 3.0[4]	13.6 ± 3.8[5]	15.2 ± 5.5[5]	23.0 ± 5.6[5]**	42.4 ± 12.6[5]**	143.8	45.9
Cholesterol (mg/dL)	87.7 ± 2.8[10]**	89.0 ± 2.8[5]	82.6 ± 0.7[5]	93.8 ± 7.5[5]	97.0 ± 3.2[5]	94.8 ± 5.4[5]	134.8 ± 8.1[5]**	238.4	147.3
Glucose (mg/dL)	135.0 ± 6.7[10]**	144.6 ± 6.1[5]	129.8 ± 1.8[5]	135.0 ± 6.4[5]	127.8 ± 2.5[5]	130.2 ± 15.6[5]	104.8 ± 2.4[5]**	360.3	183.9

Values given as mean ± SEM [N].
Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.
Statistical significance for the control group indicates a significant trend test.
Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.
* Statistically significant at p <= 0.05
** Statistically significant at p <= 0.01
Clinical chemistry data not reported were removed as an outlier, or due to pre-analytical or analytical conditions or errors including but not limited to: below linearity, short sample, quantity not sufficient, or extreme hemolysis
BMD_{1Std} and $BMDL_{1Std}$: Benchmark response (BMR) set at 1 standard deviation from the mean.

** END OF REPORT **